RxDoctor Payments Data

Aram Minasian, MD

Internal Medicine · Grand Blanc, MINPI 1679546303

Payments from drug & device makers

$7,975in general payments, 2019–2025

Across 482 payments — averaging $16.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • GSK$818
  • Lilly USA, LLC$817
  • AbbVie$569
  • Corcept Therapeutics$421
  • Bayer$347
  • plus $3K from 40 others

What the payments were for

  • Food & beverage$7,82098%
  • Education$1552%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,975 in reported general payments places this provider in the 90th percentile of 4,567 internal medicine providers in Michigan.

See all internal medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$83,713
Medicare patients
169
Services billed
1,907

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban128$114,585
MounjaroTirzepatide93$99,831
OzempicSemaglutide79$81,519
JardianceEmpagliflozin36$36,023
XareltoRivaroxaban28$26,427
TrulicityDulaglutide16$22,262
LinzessLinaclotide22$20,042
Trelegy ElliptaFluticasone/Umeclidin/Vilanter28$17,727
JanuviaSitagliptin Phosphate11$15,935
JanumetSitagliptin Phos/Metformin Hcl14$15,506
Repatha SureclickEvolocumab16$9,562
Atorvastatin Calcium534$8,926
Repatha SyringeEvolocumab11$8,015
Duloxetine Hcl222$6,742
Losartan Potassium398$6,075

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$817$122,093109 claims
PfizerEliquis$164$114,585128 claims
Novo NordiskOzempic$1,583$81,51979 claims
Boehringer IngelheimJardiance$124$36,02336 claims
MerckJanuvia, Janumet$33$31,44125 claims
AbbVieLinzess$569$20,04222 claims
GSKTrelegy Ellipta$818$17,72728 claims
AstraZenecaPulmicort Flexhaler$189$3,39318 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,567 internal medicine providers in Michigan.

Other internal medicine in Grand Blanc

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →